Allosteric activators of the ALPHA1A-adrenergic receptor

A compound of formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein:
• R1 is a 5-membered heterocyclyl ring having 1, 2, or 3 nitrogen atoms;
• R2 is —X—(CH2)m—, wherein X is selected from —O—, —NH—, —S—, and —CH2—, and wherein m is 0, 1, or 2;
• R3 is selected from C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C6 hydroxyalkyl, C2-C6 haloalkyl, C2-C6 hydroxyhaloalkyl, C3-C6 cycloalkyl, aryl, halo, a hydrophobic amino acid moiety, and —(CHRa)n—R6, wherein:
• Ra is selected from hydrogen and hydroxy;
• n is 1 or 2;
• and
• R6 is selected from aryl, C3-C6 cycloalkyl, a 3- to 6-membered heterocyclic ring having 1, 2, or 3 heteroatoms selected from O, N, and S;
• R4 is selected from —NRb—SO2—R7, —(CRcRd)—SO2—R7, and —(CReRf)p—R8, wherein:
• Rb is selected from hydrogen, C1-C3 alkyl and C1-C3 haloalkyl;
• Rc and Rd are each independently selected from hydrogen and methyl, or Re and Rd are taken together with the carbon atom to which they are attached to form a C3-C4 cycloalkyl group;
• Re and Rf are each independently selected from hydrogen and halo;
• p is 0 or 1;
• R7 is selected from hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, and C3-C6 cycloalkyl;
• and
• R8 is selected from C1-C4 alkoxy, C1-C4 haloalkoxy, hydroxy, —COOH, —CONH2, and a 5-membered heteroaryl having 1, 2, or 3 nitrogen atoms;
• and
• R5 is selected from hydrogen, halo, and any of the groups indicated for R3 and R4;
• wherein each aryl, heteroaryl, cycloalkyl, and heterocyclyl can be independently unsubstituted or substituted with 1, 2, or 3 substituents independently selected from hydroxy, halo, C1-C3 alkyl, C1-C3 haloalkyl, and oxo.